Why Cefepime is on the WHO Reserve Antibiotic List
Cefepime is NOT on the WHO Reserve antibiotic list—it was actually excluded from WHO essential medicines recommendations due to concerns about increased mortality and was considered redundant to other listed antibiotics. 1
The Evidence Behind Cefepime's Exclusion
The 2024 WHO guidelines explicitly state that cefepime was not included in their essential medicines list because it was considered redundant to antibiotics already listed (such as ceftriaxone and piperacillin-tazobactam) and because of concerns about increased mortality 1. The Working Group proposed adding cefepime to the Watch list, but the Expert Committee ultimately decided against its inclusion.
Mortality Concerns
The mortality signal associated with cefepime stems from a landmark 2007 systematic review and meta-analysis that found:
- All-cause mortality was significantly higher with cefepime compared to other beta-lactams (risk ratio 1.26,95% CI 1.08-1.49) 2
- This mortality signal was even stronger in trials with better methodological quality (RR 1.52 for trials with adequate allocation-sequence generation) 2
- No differences were found in treatment failure, superinfection, or adverse events—only mortality 2
This mortality concern has been reinforced by recent evidence showing cefepime recipients experienced 21% fewer delirium- and coma-free days compared to piperacillin-tazobactam in the ACORN trial, highlighting the clinical significance of cefepime-induced neurotoxicity (CIN), particularly in patients ≥65 years old 3.
WHO's AWaRe Classification Framework
The WHO AWaRe system categorizes antibiotics into three groups:
- Access: First-line antibiotics with narrow spectrum and low resistance potential
- Watch: Broader-spectrum antibiotics with higher resistance risk that should be prioritized as key targets for stewardship
- Reserve: Last-resort antibiotics for multidrug-resistant infections
Cefepime, when listed by countries, typically falls into the Watch category 4, not Reserve. The Reserve category is reserved for antibiotics like carbapenems, colistin, and newer agents specifically for multidrug-resistant organisms.
Clinical Context and Current Use
Despite WHO's exclusion, cefepime remains widely used globally because:
- It has broad-spectrum activity against both Gram-positive and Gram-negative bacteria 5
- It demonstrates stability against many beta-lactamases and is a poor inducer of type I beta-lactamases 6, 7
- It provides coverage for Pseudomonas aeruginosa and CESP group organisms (Citrobacter, Enterobacter, Serratia, Providencia) 8
However, only 13.4% of cefepime prescriptions meet all criteria for proper use 8, highlighting the need for enhanced antimicrobial stewardship.
Key Safety Considerations
Cefepime-induced neurotoxicity is underrecognized and particularly dangerous in elderly patients and those with renal impairment 3. The FDA label requires dose adjustment when creatinine clearance is ≤60 mL/min 5, but active surveillance for neurotoxicity is often lacking in clinical practice.
Bottom Line
Cefepime is not a Reserve antibiotic. The WHO excluded it from essential medicines recommendations entirely due to mortality concerns and redundancy with safer alternatives like ceftriaxone and piperacillin-tazobactam. When countries do list cefepime, it appropriately belongs in the Watch category, requiring careful stewardship and monitoring for neurotoxicity, especially in vulnerable populations.